

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.comhttps://practicaldermatology.com/conferences/maui-derm-hawaii-2025/new-drugs-and-therapies-in-2025-dr-bhatia/32688/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

New Drugs and Therapies in 2025: Dr. Bhatia

Neal Bhatia:

Hi, I'm Neal Bhatia and at Maui Derm I was part of our annual, the traditional New Drugs in Derm that Ted Rosen and I put together. This year, the zombies made an appearance, which was quite fun, but we had a good recap of some of the biologics that have been launched, some of the JAK inhibitor data, safety data, especially some comparison data between the two.

More importantly, we talked about intralesional therapies coming for non-melanoma skin cancer, both the cemiplimab as well as an oncolytic peptide known as LTE315. Both of these have some really interesting early data that will show itself later and hopefully be a good adjunct for us in addition to surgery as well as on its own.

Some of the other topics were some devices as well as, again, some new updates in the topicals for atopic dermatitis, both tapinarof and roflumilast, both being launched, as well as some updated data on ruxolitinib for lichen planus as well as hidradenitis suppurativa. Speaking of which, we talked about the povorcitinib data and how that's going to basically change the game just like remibrutinib will for chronic spontaneous urticaria.

A lot of good opportunities coming in the next year, a lot of good launches that basically came out, but even more so we'll see some things that are in late phase start to reach the market. Pretty good time to follow the pipeline, follow the therapeutic ladder, and let's see where things go.